Effectiveness of Pharmacokinetic/Pharmacodynamic-Guided Meropenem Treatment in Critically Ill Patients: A Comparative Cohort Study.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
14
04
2020
accepted:
25
09
2020
pubmed:
6
11
2020
medline:
16
11
2021
entrez:
5
11
2020
Statut:
ppublish
Résumé
The proper dosage of antibiotics is a key element in the effective treatment of infection, especially in critically ill patients. This study aimed to evaluate the efficacy of optimized meropenem regimens based on pharmacokinetic/pharmacodynamic criteria in patients admitted to the intensive care unit. This observational, naturalistic, retrospective, unicentric cohort study was performed between May 2011 and December 2017. The clinical and bacteriologic responses of 77 control intensive care unit patients receiving meropenem were compared with those of 77 propensity score-balanced patients who received meropenem dose adjusted by therapeutic drug monitoring. The primary end point of clinical response was a reduction at the end of treatment of at least 80% of the maximum procalcitonin (PCT) value recorded during the meropenem treatment. The primary end point was met by 55 patients (71.4%) in the adjusted group compared with 41 (53.3%) patients in the control group (mean difference 18.1%, P = 0.02). Fifty-one patients (66.2%) in the adjusted group required a meropenem dose adjustment, being necessary in 46 of them (90.2%) to decrease the dose. The reduction of PCT was the greatest in the adjusted group compared with the unadjusted group (93% versus 85%, P = 0.004); a greater percentage of patients reached a PCT level < 0.5 ng/mL (63.6% versus 41.6%, P = 0.006), and there was a trend toward an improved bacteriologic response (relative risk = 1.27; 95% confidence interval: 0.92-1.56). There were no differences in early mortality or safety between groups. Adjustment of meropenem therapy by monitoring is a useful strategy for improving meropenem effectiveness in the treatment of infection in critically ill patients, with no impact on safety.
Sections du résumé
BACKGROUND
The proper dosage of antibiotics is a key element in the effective treatment of infection, especially in critically ill patients. This study aimed to evaluate the efficacy of optimized meropenem regimens based on pharmacokinetic/pharmacodynamic criteria in patients admitted to the intensive care unit.
METHODS
This observational, naturalistic, retrospective, unicentric cohort study was performed between May 2011 and December 2017. The clinical and bacteriologic responses of 77 control intensive care unit patients receiving meropenem were compared with those of 77 propensity score-balanced patients who received meropenem dose adjusted by therapeutic drug monitoring. The primary end point of clinical response was a reduction at the end of treatment of at least 80% of the maximum procalcitonin (PCT) value recorded during the meropenem treatment.
RESULTS
The primary end point was met by 55 patients (71.4%) in the adjusted group compared with 41 (53.3%) patients in the control group (mean difference 18.1%, P = 0.02). Fifty-one patients (66.2%) in the adjusted group required a meropenem dose adjustment, being necessary in 46 of them (90.2%) to decrease the dose. The reduction of PCT was the greatest in the adjusted group compared with the unadjusted group (93% versus 85%, P = 0.004); a greater percentage of patients reached a PCT level < 0.5 ng/mL (63.6% versus 41.6%, P = 0.006), and there was a trend toward an improved bacteriologic response (relative risk = 1.27; 95% confidence interval: 0.92-1.56). There were no differences in early mortality or safety between groups.
CONCLUSIONS
Adjustment of meropenem therapy by monitoring is a useful strategy for improving meropenem effectiveness in the treatment of infection in critically ill patients, with no impact on safety.
Identifiants
pubmed: 33149053
pii: 00007691-202104000-00009
doi: 10.1097/FTD.0000000000000826
doi:
Substances chimiques
Anti-Bacterial Agents
0
Meropenem
FV9J3JU8B1
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-263Informations de copyright
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Craig WA, Ebert S, Watanabe Y. Differences in time above the MIC (T>MIC) required for efficacy of beta-lactams in animal infection models, abstr 86. In: Prog. Abstr. 35th Intersci. Conf. Antimicrob. Agents Chemother. San Francisco, WA: CA American Society for Microbiology; 1993.
Mattoes HM, Kuti JL, Drusano GL, et al. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther. 2004;26:1187–1198.
Bustamante CI, Drusano GL, Tatem BA, et al. Postantibiotic effect of imipenem on Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;26:678–682.
Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial β-lactam concentration in select critically ill patients. Chest. 2012;142:30–39.
Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725–1730.
Tam VH, Schilling AN, Neshat S, et al. Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2005;49:4920–4927.
Roberts JA, Ulldemolins M, Roberts M, et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents Chemother. 2010;36:332–339.
Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49:1–16.
Woksepp H, Hallgren A, Borgstrom S, et al. High target for β-lactam antibiotic in intensive care unit patients when actual minimum inhibitory concentrations are applied. Eur J Clin Microbiol Infect Dis. 2017;36:553–563.
Schuetz P, Beishuizen A, Broyles M, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019;57:1308–1318.
Rodvold KA, Blum RA. Predictive performance of Sawchuck-Zaske and Bayesian dosing methods for tobramycin. J Clin Pharmacol. 1987;27:419–424.
Méndez A, Steppe M, Schapoval E, et al. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal. 2003;33:947–954.
Zysset T, Zeugin T. Comparison of the Amicon Centrifree micropartition system with the Sartorius SM 13249E Centrisart I device to determine protein free phenytoin concentrations. Ther Drug Monit. 1986;8:346–351.
Zysset T, Hegel A. Comparison of the Beckman TL-100 ultracentrifuge with the Amicon Centrifree Micropartition filters to determine protein-free phenytoin concentrations. Ther Drug Monit. 1987;9:433–438.
Flamant M, Haymann JP, Vidal-Petiot E, et al. GFR estimation using the Cockcroft-gault, MDRD study, and CKD-EPI equations in the elderly. Am J Kidney Dis. 2012;60:847–849.
Demirovic JA, Pai AM, Pai MP, et al. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm. 2009;66:642–648.
Idoate AI, Aldaz A, Marquet P, et al. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation. Eur J Clin Pharmacol. 2019;75:1405–1414.
Neely MN, Van Guilder MG, YamadaWM, et al. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Ther Drug Monit. 2012;34:467–476.
Carlier M, Carrette S, Roberts JA, et al. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used? Crit Care. 2013;17:R84.
Al-Shaer M, Wael A, Graham, et al. M eropenem, cefepime, and piperacillin protein binding in patient samples. Ther Drug Monit. 2020;42:129–132.
Wong G, Briscoe S, Adnan S, et al. Protein binding of -lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57:6165–6170.
Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27:887–892.
Crist KD, Nahata MC, Ety J. Positive impact of a therapeutic drug-monitoring program on total aminoglycoside dose and cost of hospitalization. Ther Drug Monit. 1987;9:306–310.